The case for & against
Bull & Bear analysis
Bullish
MacroGenics, Inc. (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company specializing in developing novel antibody-based therapies for cancer treatment. MacroGenics is particularly focused on antibody-drug conjugates (ADCs) and bispecific T-cell engagers targeting solid tumors, especially those expressing the B7H3 antigen. The company's innovative approach positions it well within the evolving oncology landscape as it seeks to address significant unmet medical needs and improve patient outcomes through its expanding clinical pipeline.
Bull says
- ↑Q3 2024 revenue reached $110.7M, up from $10.4M YoY on an $85M milestone
- ↑Net income surged to $56.3M in Q3 versus $17.6M prior year, highlighting profitability
- ↑LIMITS Phase 2 trial for loradrolumab in ovarian cancer slated to begin early 2025
- ↑Tamarack Phase II trial shows strong enrollment, underscoring clinical demand
- ↑Cash position of ~$201.7M end-2024 supports R&D and operations
- ↑Reasonable book-to-price valuation, strong liquidity and high institutional interest
Bear says
- ↓Q1 2024 revenue plunged to $9.1M versus $24.5M YoY due to lower partner payments
- ↓Heavy reliance on unpredictable milestone payments could destabilize revenue
- ↓R&D expenses rose to $177.2M in 2024 from $166.6M in 2023, pressuring cash
- ↓Clinical trial setbacks, particularly in Tamarack, add execution and outcome risks
- ↓Weak profitability metrics and low analyst revisions point to shaky fundamentals
- ↓High cash-flow volatility and limited market influence may deter investors
Earnings Call · Q3 2023 · Mgmt. Guidance
Updated 09-01-2026neutral
Transcript signals
Bull points
- We feel that given what Synapse has already shown with regard to what we believe is superiority platform, the ability of using a DIR in this case close to four of the exotecan in various configurations and our own preclinical data showing the favorable aspects of this.
- And I think that the pace we are at right now is quite favorable where, you know, we're pushing the team to be able to have a new IMD on an annual or slightly longer basis. This would provide both opportunities for organic growth, but also given the importance of bringing in non-dilutive capital, the opportunity for partnerships there.
- Well, I think actually we're in wonderful shape and giving greater opportunities for patients. We think that it provides greater opportunity and choices for treating particularly patients, but most importantly, with regard to this particular program, having an ADC for B7H3 versus an ADC for PSMA, PSMA is going to be largely limited to prostate cancer, whereas with a broad expression of B7H3 across most solid tumors, I think that we are in great opportunity not only for patients with prostate cancer, but through a whole host of other tumors.
Bear points
- again, we have always had a very close relationship with and had discussions with them on where the value we see in settings like a neoadjuvant use of this drug.
- Again, we have reported, and what I just described to Daichi with approximately a quarter of those patients have objective responses without even higher levels.
- MacroGen's total revenue was $10.4 million for the quarter ended September 30, 2023, compared to total revenue of $41.7 million for the quarter ended September 30, 2022. The decrease reflects the recognition of $30 million in revenue under the Insight License Agreement during the three months ended September 30, 2022.
Read full transcript analysis ›